Why Alnylam Pharmaceuticals Stock Was Soaring on Monday

Core Viewpoint - Alnylam Pharmaceuticals' stock experienced a significant increase of over 6% following positive analyst notes, particularly an upgrade from Freedom Capital Markets [1][2]. Analyst Recommendations - Ilya Zubkov of Freedom Capital Markets upgraded his recommendation on Alnylam from hold to buy, while lowering the price target from $470 to $410 per share [2]. - Canaccord Genuity's Whitney Ijem also raised her price target for Alnylam from $415 to $429 per share, indicating a more bullish outlook [6]. Company Performance - Alnylam recently reported its fourth-quarter and full-year 2025 results, which disappointed investors due to a revenue miss despite a bottom-line beat [4]. - Zubkov highlighted the strong performance of Amvuttra, a drug targeting transthyretin amyloid cardiomyopathy (ATTR-CM), noting robust sales in both domestic and international markets [5]. Market Sentiment - There is a belief among some analysts that investors reacted too harshly to Alnylam's earnings release, with optimism surrounding Amvuttra's growth potential [7].